HANSIZHUANG ® (serplulimab) was the first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC – ...
New study shows that AI can predict lung cancer from digitized patient tissue samples rapidly and with a high degree of ...
A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, ...
Treatment of non-small cell lung cancer (NSCLC) depends on the stage you're in and can include chemotherapy, surgery, ...
A team of doctors and researchers at MSK have identified a new, rare type of small cell lung cancer that primarily affects younger people who have never smoked. Learn how one 19-year-old patient ...
A new strategy to treat a common form of lung cancer focuses on a protein whose loss makes it harder for the body to repair ...
Lung cancer is tied to tobacco smoking in the public consciousness, but a significant proportion of cases are driven by ...
Phase Ib met its primary endpoint, demonstrating a meaningful objective response rate (ORR) of 66.7%, as assessed by blinded ...
The study didn’t test ivonescimab against the Keytruda and chemotherapy combination that’s now standard treatment for most non-small cell lung cancer cases. It was also run only in China, making a ...
We quantified the proportion of diagnoses of pulmonary fibrosis (PF) among 25 136 people with lung cancer and 250 583 matched ...
Patients with vs without rheumatoid arthritis (RA), especially those with RA-associated interstitial lung disease (RA-ILD), have a significantly higher risk of developing lung cancer, according to ...
Lung cancer screening experts from around the globe delivered strategies and best practices for improving access to screening ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback